| Target | PD-1 |
|---|
| Application | FC, IHC |
|---|
| Clonality | Monoclonal |
|---|
| Conjugate | Allophycocyanin (APC) |
|---|
| Isotype | Human IgG1κ |
|---|
| Immunogen | Human PD-1 |
|---|
| Species Reactivity | Human, Cynomolgus Monkey |
|---|
| Formulation | This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
|---|
| Research Area | Cancer, Immunology |
|---|
| Description/Background | Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects. |
|---|
| Storage Temperature | This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. |
|---|
| Protocols | FC, IHC |
|---|
| Clone Number | 5C4.B8 |
|---|
| Concentration | 0.2 mg/ml |
|---|
| Endotoxin levels | < 1.0 EU/mg as determined by the LAL method |
|---|
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
|---|
